Crystalline Lucerastat Salts for Humidity-Stable Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for additional solid state forms of Lucerastat: Salicyclic acid salt and Lucerastat: L-pyroglutamic acid salt that offer superior properties without altering the pharmacological properties, particularly for improved handling, stability, and bioavailability, as existing forms may deliquesce under high humidity and have variable dissolution profiles.
Innovation Solution
The development of Lucerastat: Salicyclic acid salt and Lucerastat: L-pyroglutamic acid salt in the form of isolated, crystalline solids with controlled humidity resistance and stability, characterized by specific X-ray powder diffraction patterns, to enhance handling and stability, and their use in pharmaceutical compositions for treating Fabry disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing solid state forms of Lucerastat salts are used, then the pharmacological properties are maintained, but the handling and stability are compromised due to deliquescence under high humidity
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical parameters of Lucerastat salts through salt formation with different acids (salicylic acid, L-pyroglutamic acid, fumaric acid, benzoic acid, o-acetylsalicylic acid). This changes the molecular structure and intermolecular forces, resulting in salts with reduced hygroscopicity and improved stability under humid conditions while maintaining the pharmacological activity of the parent compound.
Solution Approach 2:
The patent creates composite materials by forming salts between Lucerastat (the active pharmaceutical ingredient) and various co-formers (acids). These composite salt forms combine the pharmacological properties of Lucerastat with the stabilizing characteristics of the co-formers, producing materials that resist deliquescence and offer improved handling and storage properties.
2Adaptability or versatility
If existing solid state forms of Lucerastat salts are used, then the formulation is simplified, but the dissolution profile is variable affecting bioavailability
Solution Approach 1:
The patent modifies the dissolution profile by changing the salt form parameters. Different acids produce salts with varying solubility and dissolution rates, allowing optimization of the dissolution profile to ensure consistent and reliable bioavailability of the active ingredient.
3Ease of operation
If new solid state forms are developed, then handling and stability are improved, but the manufacturing process becomes more complex
Solution Approach 1:
The patent employs preliminary action by pre-forming stable salt compounds of Lucerastat with selected acids before final formulation. These pre-formed salts possess inherent stability and handling advantages, simplifying subsequent formulation and manufacturing steps despite the additional salt formation step required.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new solid state forms provide improved chemical and physical stability, reduced hygroscopicity, and consistent dissolution profiles, ensuring effective treatment of Fabry disease with enhanced handling and storage characteristics.
Implementation Method 1
characterized by specific X-ray powder diffraction patterns
Implementation Method 2
wherein the salt can be isolated as a solid, or particularly wherein the salt is isolated as a solid, and moreover remains solid when exposed to 20-80% relative humidity (RH) for 7 days
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure encompasses solid state forms of Lucerastat, in embodiments crystalline Lucerastat: L-Pyroglutamic acid, crystalline Lucerastat: Salicylic acid, crystalline Lucerastat: Fumaric acid, crystalline Lucerastat: Benzoic acid and crystalline Lucerastat: o-Acetylsalicylic acid, solid state form thereof, processes for preparation thereof, and pharmaceutical compositions thereof.